Teva Pharma (TEVA) Gets Final U.S. FDA Approval for Generic Prevacid
More News related to TEVA
- Protalix BioTherapeutics (PLX) Sees Interest On Renewed Takeover Talk
- Abbott (ABT) sues Teva (TEVA) over its drug for kidney patients, Zemplar
- Merriman Curhan Ford Initiates Coverage on Antares Pharma (AIS) with a Buy; Cutting Edge Drug Delivery Business
- Teva Pharma (TEVA) Gets Final U.S. FDA Approval for Generic Prevacid
- Teva Receives Final Approval for Generic Prevacid(R) Delayed-Release Capsules
More News related to Corporate News
- Canaccord Adams Maintains a 'Buy' on Protalix BioTherapeutics (PLX); Cerezyme Supply on Track, See More Uplyso EAP Uptake
- Bove Says US Banking System, Dollar to Benefit from Dubai Crisis
- Broadpoint.AmTech Says Solar Inventory Getting Healthier into Year-end
- UBS Maintains a Neutral rating on American Eagle Outfitters (AEO); Lowers Estimates Through 2011
- Barclays Reiterates an 'Overweight' on Deere (DE); Adjusts Estimates & PT
Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) announced today that the U.S. Food and Drug Administration has granted final approval for the Company's Abbreviated New Drug Application (ANDA) to market its generic version of Tap Pharmaceutical's proton pump inhibitor Prevacid (lansoprazole) Delayed-Release Capsules, 15 mg and 30 mg. Customers will begin receiving product on November 11, 2009.
Annual sales of Prevacid Delayed-Release Capsules were approximately $2.97 billion in the United States for the twelve months that ended June 30, 2009 based on IMS sales data.
Related Categories
Corporate NewsFDA
Stocks Mentioned
-0.28Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
